A Study Assessing KB407 for the Treatment of Cystic Fibrosis
Phase 1
12
about 2.6 years
18+
5 sites in FL, IL, NC +1
What this study is about
Researchers are testing a treatment called KB407, given through nebulization, to see if it's safe and well-tolerated in adults with cystic fibrosis. The trial will last approximately 946 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive KB407 (Nebulization)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: To evaluate safety and tolerability of KB407 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in physical examinations, vital signs, ECG, and clinical laboratory test results
Secondary: To evaluate the effects of KB407 on pulmonary function, as measured by change from baseline in absolute and percent predicted FEV1
Respiratory